Sleep Disorders

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Neurology News Network for the week ending October 7, 2023. [WATCH TIME: 3 minutes]

Michael Grandner, PhD, associate professor of psychiatry at the University of Arizona College of Medicine, discussed Sleep Reset, an app-based, personalized sleep program that uses sleep coaches to help guide patients in the care of their sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 6, 2023.

Elena Koundourakis, PhD, head of orexin franchise development at Takeda, talked about the phase 2 trial investigating TAK-994 in patients with narcolepsy type 1, which showed significant improvements in wakefulness, despite discontinuation because of hepatotoxicity.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Neurology News Network for the week ending September 30, 2023. [WATCH TIME: 4 minutes]

The AI-based SOMNUM technology uses diagnostic algorithms based on multi-channel/time series sleep biosignal data to deliver fast, accurate diagnostic information for providers.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 29, 2023.

The phase 3 SYMPHONY trial assessing AXS-12, a selective norepinephrine reuptake inhibitor for narcolepsy, was initially expected in the third quarter of 2023.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 22, 2023.

On World Narcolepsy Day 2023, get a recap of the latest advances in narcolepsy that you might have missed over the last few months, compiled all into one place by the NeurologyLive team.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Birgitte Kornum, MD. [LISTEN TIME: 18 minutes]

In a large cohort of 848 pediatric participants with challenge-proven food allergy, investigators identified narcolepsy-like sleepiness as a symptom impacting more than 1 in 10 patients with food allergies.

In a recent long-term analysis of a phase 3 trial, the most common treatment-emergent adverse events that led to discontinuation of low-sodium oxybate were cataplexy, headache, nausea, and psychiatric disorders.

Sodium oxybate, an endogenous GHB/GABAB receptor agonist, is clinically used to promote slow-wave sleep and reduce next-day sleepiness in disorders such as for patients with narcolepsy

Here's some of what is coming soon to NeurologyLive® this week.

Acute and sustained treatment with ulotaront did not show a statistically significant decrease from placebo in total number of cataplexy events and had no significant change in other symptomatic ratings over a 2-week treatment period.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer and dementia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 15, 2023.

In a recent study on patients with narcolepsy type 1, those who used opioid drugs such as oxycodone and codeine were significantly associated with improved self-reported narcolepsy symptom severity.

A recent systematic review and meta-analysis showed that normal mean sleep latency in adults was 11.7 minutes using the earlier definition of sleep onset and 11.8 minutes using the later definition of sleep onset.